Inmunotek

Executive Summary

Inmunotek, founded in 2005 and headquartered in Madrid, Spain, is a privately held biopharmaceutical company specializing in the development and commercialization of immunotherapies for allergic and immune-based diseases. The company leverages sublingual and subcutaneous immunotherapy platforms for both human and veterinary applications, operating GMP-certified manufacturing facilities. With approved products marketed in over 50 countries, Inmunotek has established a strong commercial footprint in the allergy immunotherapy space, differentiating itself through a broad portfolio and global reach. The company's focus on both human and animal health positions it uniquely in the biologics sector, addressing a large and growing market for allergy treatments worldwide.

Upcoming Catalysts (preview)

• Q4 2026FDA approval of allergy immunotherapy product for US market40% success
• Q2 2027Positive Phase III data for a novel sublingual immunotherapy candidate55% success
• Q3 2026New commercial partnership for distribution in Asia-Pacific region70% success